Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mining The Data: WellPoint Stresses Need For Context In Safety Surveillance

This article was originally published in The Pink Sheet Daily

Executive Summary

WellPoint is exploring ways to more accurately identify adverse events as it builds a drug safety monitoring system.

You may also be interested in...

FDA Post-Market Safety Efforts Won’t Be Impacted By Sentinel In Near Term

FDA's Sentinel post-market safety monitoring project will augment, not replace, the agency's current repertoire of post-market activities and requirements for drugs, Center for Drug Evaluation and Research Director Janet Woodcock emphasized

WellPoint Drug Safety Monitoring System Expected To Go Live In Mid-2009

WellPoint is developing a post-marketing drug safety monitoring system that will be capable of drawing data from the 25 million members in its integrated medical and pharmacy insurance plans

340B Showdown: HHS Facing Mounting Congressional Pressure To Halt Pharma Challenges

Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts